New pill aims to restore skin color in vitiligo patients
NCT ID NCT07556471
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental pill called LW402 in 180 adults with non-segmental vitiligo, a condition that causes white patches on the skin. The pill works by blocking certain immune signals. Participants will take one of three doses or a placebo for up to 52 weeks to see if it helps bring back skin color, especially on the face. The goal is to find a safe and effective treatment to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Aged 18 to 75 years (inclusive), with no restriction on gender; * Clinically diagnosed with non-segmental vitiligo at screening; * At the screening visit and baseline visit, the Facial Vitiligo Area Scoring Index (F-VASI) is ≥ 0.5 and the Total Vitiligo Area Scoring Index (T-VASI) is ≥ 3; * At the screening visit and baseline visit, the disease is in the progressive stage or stable stage; Exclusion Criteria: * Individuals with a known allergy to Janus kinase inhibitors； * Segmental vitiligo, mixed vitiligo, or undetermined vitiligo； * White hair is present in more than 33% of facial skin lesions due to vitiligo, or in more than 33% of total skin lesions due to vitiligo; * Skin lesions due to vitiligo are restricted to hairless areas, or hairless regions account for ≥30% of the lesion sites (e.g., lips, palms, fingers, labia); * Individuals with other active hypopigmentary conditions during the screening period (including but not limited to Vogt-Koyanagi-Harada syndrome, hypopigmentation associated with malignant tumors \[melanoma and mycosis fungoides\], post-inflammatory hypopigmentation, pityriasis alba \[a mild manifestation of atopic dermatitis\], senile leukoderma \[age-related depigmentation\], chemical/drug-induced leukoderma, ataxia-telangiectasia, tuberous sclerosis complex, melasma, and congenital hypopigmentary disorders \[including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, hereditary symmetrical dyschromatosis, xeroderma pigmentosum, and nevus depigmentosus\]) are excluded. Note: Coexisting halo nevus (also referred to as Sutton nevus) is permitted;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-segmental vitiligo (NSV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.